CSL Ltd (ASX: CSL) shares face their most important day in years on 18 August, when the plasma and vaccines giant hands down its FY26 result.
For a business that once carried an almost untouchable reputation on the ASX, the stakes are hard to overstate.
The stock fell roughly 52% across FY26, making it one of the worst performers in the S&P/ASX 200 Index (ASX: XJO).
Investors now want to know whether the worst is behind it.
Image source: Getty Images
Why CSL shares fell so hard
The decline did not begin this year. The reset started in August 2025, when the company announced a workforce reduction of up to 15% alongside a planned demerger of its influenza vaccine business.
A second downgrade followed in October, when weak flu vaccination rates forced another rethink.
Two major resets in as many quarters damaged confidence in management's forecasting.
Most of the remaining damage was done on a single day: On 11 May, an interim CEO review and financial update cut FY26 guidance for the second time in roughly six months.
Revenue was revised to approximately US$15.2 billion in constant currency, with NPATA of about US$3.1 billion before restructuring costs and impairments.
The company also flagged roughly US$5 billion in additional non-cash, pre-tax impairments spread across FY26 and FY27. CSL's own announcement says these cover Vifor intangible assets and the product portfolio, alongside under-utilised property, plant and equipment.
Interim chief executive Gordon Naylor told the market the growth initiatives were working, but that the financial benefits would take longer to materialise than management had expected.
Investors were not in a forgiving mood.
A look at CSL's recent earnings
The first-half result in February had already set a cautious tone.
Revenue came in at approximately US$8.3 billion, down 4% on the prior corresponding period, while underlying NPATA fell roughly 7% to around US$1.9 billion.
CSL Behring is the core plasma division and the engine of the entire group.
Its revenue fell about 7%, with immunoglobulin sales lower year on year despite showing sequential improvement through the half.
Higher plasma collection costs and weaker vaccine margins compounded the pressure.
The cost transformation program is the offsetting factor, and CSL is targeting US$500 million to US$550 million in annual savings by FY28.
Roughly 60% of the FY26 savings target had been achieved as at the May update.
That progress is real, but cost savings alone cannot carry a business the market once valued on growth.
What could move CSL shares on 18 August
Four things will drive the share price going forward.
The first is whether CSL Behring returned to growth in the second half.
The second is progress on the transformation program, which management has said is tracking ahead of schedule.
The third is the permanent chief executive appointment, with a global search running since February.
The fourth is the CSL Seqirus demerger, which was deferred in October 2025 and still has no confirmed completion date.
Commercial leadership also passed to Diego Sacristan on 1 July, so any shift in strategic emphasis will be worth listening for on the call.
Investors should also watch the dividend, which is paid in US dollars and largely unfranked.
Foolish takeaway
CSL shares have rebounded strongly from their June lows without coming close to erasing the decline, leaving this result finely balanced.
A credible second-half recovery in Behring would suggest the market overshot on the way down.
Another guidance reset would confirm the bear view that this is a structural problem rather than a cyclical one.
The plasma collection business still has scale advantages and high barriers to entry.
But Vifor has proved an expensive mistake, and the leadership vacuum does not help.
For anyone weighing CSL shares today, 18 August is the date that may resolve the question.
